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Summary
Background: The use of rifampicin for cholestatic pruritus is accompanied by
concerns over safety, but the availability of real-world prescribing data is relatively
limited.
Aim: We sought to describe the rate and characteristics of rifampicin-induced hep-
atitis in a mixed aetiology cohort of patients with established liver disease and cho-
lestatic pruritus.
Methods: Retrospective review of records for out-patients commenced on rifampi-
cin for pruritus 2012-2016 inclusive. Rifampicin-induced hepatitis was recorded
where alanine aminotransferase activity (ALT) increased to both ≥5 9 baseline and
≥5 9 upper limit of normal (ULN), or to both ≥3 9 baseline and ≥3 9 ULN with
concurrent elevation in serum bilirubin to ≥2 9 baseline and ≥2 9 ULN, in addition
to a Roussel-Uclaf Causality Assessment Method score of “probable” or “highly
probable” for rifampicin causality.
Results: After exclusions, we reviewed 105 patients who took rifampicin for a med-
ian of 131 days. Most had primary biliary cholangitis or primary sclerosing cholangi-
tis; 40 (38.1%) were men and median age was 44 years (IQR: 32-57). 44 (41.9%)
patients had baseline serum bilirubin ≥2 9 ULN and 28 (26.7%) ALT ≥3 9 ULN. 5
(4.8%) developed rifampicin-induced hepatitis at a median of 70(range 27-130) days
after drug initiation. No individual or laboratory baseline characteristics were signifi-
cantly associated with subsequent development of hepatitis. All cases of hepatitis
recovered after drug cessation, although one patient was hospitalised and received
corticosteroids.
Conclusions: Given the efficacy of rifampicin for an important sub-group of those
with cholestatic pruritus, adult patients, including those with jaundice, can be coun-
selled that 95% of prescriptions are safe, and where hepatitis occurs, including at
long latency, drug cessation appears effective.
The Handling Editor for this article was Professor Peter Hayes, and it was accepted for publication after full peer-review.
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1 | INTRODUCTION
Pruritus is a frequent and distressing complication of liver disease,
especially cholestatic liver disease.1 The antimicrobial drug rifampicin
(USAN: rifampin) is recognised as a therapeutic agent for pruritus
having shown efficacy in the majority of controlled trials,2-6 and is
currently recommended by major international guidelines in the ther-
apy of pruritus in cholestatic liver disease.7,8
Rifampicin has been reported to be associated with hepatitis in a
minority of patients receiving the drug as therapy for mycobacterial
infections.9,10 This is especially the case where there is combination
therapy with other potentially hepatotoxic agents11 and is associated
with a variety of risk factors12 To date meta-analyses of previous
controlled studies of rifampicin for pruritus have concluded that the
treatment is safe, with the largest study of 61 patients recording no
clinically significant episodes of hepatitis.13,14 However, despite
these meta-analyses, individual reports of rifampicin-induced hepati-
tis during therapy for pruritus do exist including with occurrence
after the short-term follow-up typically used in trials.15,16 It remains
uncertain as to how best to counsel patients being prescribed rifam-
picin off-label for therapy of cholestatic pruritus given a lack of esti-
mates regarding its potential to cause liver injury. This is especially
the case in those with pre-existing jaundice.
Given the immediate utility to prescribers, we have evaluated
the occurrence of hepatitis in a cohort of 105 patients with estab-
lished liver disease of mixed aetiology in whom rifampicin was pre-
scribed for pruritus. In so doing, we provide real-world data of use
to all prescribers when counselling patients.
2 | METHODS
With the permission of University Hospitals Birmingham, a retro-
spective review of cases notes of all patients attending University
Hospitals Birmingham on an out-patient basis from 2012 to 2016
inclusive and who received new prescriptions for rifampicin without
concurrent isoniazid was conducted. Details of demographics, labora-
tory variables and clinical course were reviewed.
Cases were considered to represent rifampicin-induced hepatitis if
laboratory values met the criteria of the DILI Expert Working Group:17
1. either, a rise in serum aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) activity to both ≥5 9 pre-rifampicin base-
line and ≥5 9 upper limit of normal (ULN);
2. or, a rise in ALT or AST to both ≥3 9 pre-rifampicin baseline and
≥3 9 ULN with a concurrent rise in serum bilirubin to both
≥2 9 pre-rifampicin baseline and ≥2 9 ULN;
3. and, a Roussel-Uclaf Causality Assessment Method (RUCAM)
score of ≥6 (“Probable” or “Highly probable”) for rifampicin
hepatitis.18
Comparative statistics were used to compare groups that did,
and that did not, develop hepatitis whilst taking rifampicin: the
chi-squared test was used to compare categorical variables whilst
the Mann–Whitney U-test was used to compare non-normally dis-
tributed numeric variables with normality assessed using the Sha-
piro-Wilk test; a P value of < 0.05 was considered significant.
Analyses were performed with StataMP v15.0 (StataCorp, College
Station, TX, USA)
3 | RESULTS
We identified 116 out-patients prescribed rifampicin without concur-
rent isoniazid by the department of liver medicine between 2012
and 2016 inclusive (Figure 1). Of these, four (2.4%) prescriptions
were not made for the treatment pruritus and seven (6.0%) prescrip-
tions were never commenced. 105 patients were therefore included
in the final analysis.
One thousand three hundred and eighteen patients were pre-
scribed rifampicin without isoniazid by departments other than liver
medicine over the same time period. To assess whether these
patients had received rifampicin for pruritus, 116 records were ran-
domly selected. None had received rifampicin for pruritus: 45
(38.8%) received rifampicin for skin and wound infections; 22
(19.0%) for mycobacterium tuberculosis infections; 17 (14.7%) for
bone or joint infections; 17 (14.7%) as anti-microbial prophylaxis; 8
(6.9%) for nontuberculosis mycobacterial infections; and 7 (6.0%) for
116 rifampicin
prescriptions identified
4 prescriptions not for
7 prescriptions not
105 patients included
86 patients tolerant of 19 patients with
adverse events
6 major adverse
13 minor adverse
events
effects:
5 hepatitis
1 renal injury•
•
medication
in analysis
commenced
pruritus
F IGURE 1 Patient selection. Patient cohort selection and
exclusions from all patients prescribed rifampicin without isoniazid
by the department of liver medicine from 2012 to 2016 inclusive
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other infections. Based on the absence of prescriptions of rifampicin
for pruritus by departments other than liver medicine, only prescrip-
tions by the department of liver medicine were further evaluated.
The characteristics of the patient cohort are recorded as Table 1.
Of the 105 patients analysed, 94 (89.5%) were already prescribed
medications other than rifampicin at the point of rifampicin prescrip-
tion, with a median of 5 (IQR 3-6) nonrifampicin medications. Major
concurrent medications were 66 (62.9%) taking ursodeoxycholic acid,
33 (31.4%) proton pump inhibitors, 26 (24.8%) cholestyramine, 22
(21.0%) nonrifampicin antibiotics, 21 (20.0%) 5-aminosalicylic acid
preparations, 15 (14.3%) anti-histamines, 9 (8.6%) azathioprine or 6-
mercaptopurine, 10 (9.5%) prednisolone and 8 (7.6%) statins. Two
(1.9%) patients were prescribed concurrent sertraline and one
patient (1.0%) was prescribed naltrexone.
At baseline, many patients had significantly deranged liver
biochemistry (Table 1). 44 (41.9%) patients had a baseline bilirubin
>2 9 ULN, 23 (21.9%) patients had a baseline bilirubin ≥ 100 lmol/L
(≥ 5.8 mg/dL), and 11 (10.5%) had a baseline ALT >5 9 ULN with
28 (26.7%) >3 9 ULN.
Of the 105 patients followed up for a median of 131 days
(IQR 52-295) taking rifampicin, 5 (4.8%) patients diagnosed with
hepatitis consistent with rifampicin-induced hepatitis with a
RUCAM score ≥ 6 (Figure 2; Table 2). The median time to diagno-
sis of rifampicin-induced hepatitis was 70 days (range 27-130).
There were no significant differences in baseline characteristics
between patients who were diagnosed with rifampicin-induced
hepatitis and those that were not (Table 1). One further patient
was diagnosed with rifampicin-associated acute kidney injury with-
out associated hepatitis.
During our median follow-up of 809 days, we identified 29
patients who met biochemical criteria for potential DILI. Of these,
21 had undergone liver transplantation immediately prior to the
derangement in liver biochemistry and were not further analysed. Of
the remaining 8, 5 represented rifampicin-related DILI as assessed
by RUCAM and are described in Table 2. Three patients’ derange-
ments in liver biochemistry were scored as not related to rifampicin.
One patient reached biochemical criteria at 451 days following
rifampicin initiation with a RUCAM score of 2 and a clinical course
involving excess alcohol consumption; one at 545 days with a
RUCAM score of 2 and a clinical diagnosis of deteriorating PSC;
and one at 1239 days with a RUCAM score of 1 and with a clinical
course that involved an undiagnosed febrile illness associated with
cerebrospinal fluid lymphocytosis.
During the first 120 days of follow-up, we assessed for milder
fluctuations in liver biochemistry. Serum ALT activity rose to
≥2 9 baseline and ≥2 9 ULN in 6 (6.0%) of 101 patients not consid-
ered to have developed rifampicin induced liver injury (range 2.1-3.8
fold rise). For serum bilirubin, 5 of 101 (5.0%) patients developed
elevations to ≥2 9 baseline and ≥2 9 ULN without concurrent sig-
nificant elevations in serum ALT activity (range 2.3-3.0 fold rise).
Other than the 6 patients who developed major adverse effects,
17 (16.2%) patients reported resolution of pruritus and stopped tak-
ing rifampicin, 9 (8.6%) reported a lack of efficacy despite dose
uptitration, 13 patients (12.4%) reported intolerance (1 abdominal
discomfort, 1 discolouration of bodily secretions, 5 gastro-intestinal
disturbance, 1 localised perineal skin reaction, 1 lethargy and 4
TABLE 1 Baseline characteristics of patient cohort
Variable Hepatitis (5) No hepatitis (100) P
Gender (n)
Female 3 (60%) 62 (62.0%) 1.000
Male 2 (40%) 38 (38.0%)
Age (years + IQR) 37 (28-43) 44 (32-59) 0.257
BMI (kg/m² + IQR) 25.6 (25.5-25.9) 24.3 (21.8-27.1) 0.309
Nonrifampicin
medications (n + IQR)
5 (3-6) 4 (3-6) 0.294
Starting rifampicin
dose (mg/d)
150 0 (0.0%) 19 (19.0%) 0.479
300 5 (100%) 77 (77.0%)
600 0 (0.0%) 4 (4.0%)
Baseline laboratory values
ALT (IU/mL + IQR) 86 (85-95) 77 (41-152) 0.500
AST (IU/mL + IQR) 123 (72-191) 85 (23-131) 0.300
Bili (lmol/L + IQR) 29 (17-99) 36 (14-87) 0.630
ALP (IU/mL + IQR) 399 (272-414) 396 (221-674) 0.690
Alb (g/dL + IQR) 41 (41-44) 42 (36-45) 0.880
Primary liver diagnosis (n)
PSC 1 (20.0%) 43 (43.0%) [1] 0.900
PBC 3 (60.0%) 33 (33.0%) [3]
Congenital — 4 (4.0%)
DILI 1 (20.0%) 3 (3.0%)
Ischaemic
cholangiopathy
— 3 (3.0%) [1]
Other — 3 (3.0%)
ALD — 2 (2.0%) [1]
IgG4 — 2 (2.0%) [1]
SSC — 2 (2.0%)
Transporter
deficiencies
— 2 (2.0%)
Cancer — 1 (1.0%)
Hepatitis C — 1 (1.0%)
ICP — 1 (1.0%)
Documented alcohol
excess (n)
1 (20.0%) 3 (3.0%) 0.053
HBsAg + (n) — —
HCVAb + (n) — 2 (2.0%) —
Numbers in square brackets denote the number of patients who had pre-
viously undergone liver transplantation; P values are calculated by the
Mann–Whitney U-test or v² test as appropriate.
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; Bili, serum bilirubin; ALP, alkaline phosphatase; Alb,
albumin; PSC, primary sclerosing cholangitis; PBC, primary biliary cholan-
gitis; DILI, drug-induced liver injury; ALD, alcohol-induced liver disease;
IgG4, IgG4-related disease; SSC, secondary sclerosing cholangitis; ICP,
intrahepatic cholestasis of pregnancy.
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without a recorded reason). 21 (20.0%) received liver transplants, 3
(2.9%) were transferred to palliative care, 2 (1.9%) died, 5 (4.8%)
stopped taking rifampicin for unrecorded reasons, and 29 (27.6%)
continued to take rifampicin at the point of data collection. Figure 3
details the proportion of patients who remained free of major
adverse events, minor adverse events and who continued to take
rifampicin over the time period studied.
During treatment, 21 (20.0%) of patients received an uptitration
in their dosage of rifampicin. Two of the five patients who devel-
oped rifampicin-induced hepatitis received an uptitration in rifampi-
cin dosage prior to developing hepatitis.
Of those five patients who developed rifampicin-induced hepati-
tis, liver biochemistry resolved to baseline after cessation of rifampi-
cin in four (80%). One patient who was treated with rifampicin for
pruritus associated with primary biliary cholangitis was admitted,
underwent a liver biopsy which showed bridging fibrosis with a pat-
chy predominantly mononuclear infiltrate containing both lympho-
cytes and plasma cells, some interface hepatitis and marked-and in
places confluent-parenchymal hepatocellular necrosis. She was trea-
ted with corticosteroids with subsequent resolution of liver biochem-
istry to baseline. The one patient with acute kidney injury recovered
to baseline renal function after cessation of rifampicin.
4 | DISCUSSION
Here, we present the largest, real-world, cohort of patients treated with
rifampicin for pruritus in liver disease published to date. Within our
mixed aetiology cohort, we demonstrate that 95% of patients did not
have any concern for hepatotoxicity, but that in 5% a rifampicin-
induced hepatitis was diagnosed. This finding is in contrast with the lit-
erature from controlled trials of rifampicin for pruritus where no cases
of hepatitis were reported, but is consistent with isolated case reports
and the literature derived from tuberculosis therapy. Our hepatitis rate
of 4.8% is higher than the median of 1.1% reported for tuberculosis
treatment regimens not containing isoniazid by one meta-analysis, but
is within the range of rates reported for tuberculosis patients treated
with both isoniazid and rifampicin,11 and less than reported rates of
10%-20% for any increase in serum transaminase activity reported with
rifampicin therapy.19
Attributing liver injury to a given potential causative agent is
challenging. In this study we used the established RUCAM, which
has been widely used in other studies and has the benefit of being
points-based rather than explicitly relying on individual opinion.
However, it is important to note that recent commentary and guide-
lines have also emphasised the value of expert opinion in diagnosing
DILI.20,21 Furthermore, the RUCAM has been suggested to poten-
tially underestimate the rate of drug-induced liver injury and to
demonstrate more inter-assessor variability than other methodol-
ogy.22 In this study, we used a variation on the original RUCAM to
account for deranged baseline liver biochemistry. Although such an
adjustment is consistent with that promoted by a body expert opin-
ion, it represents a variation from the initial RUCAM specification
and is therefore likely to have differing sensitivity and sensitivity for
diagnosing DILI.17
Although the number of patients who developed rifampicin-
induced hepatitis in our cohort is small and our analysis is retrospec-
tive, there were no statistically significant distinguishing features that
predicted subsequent development of hepatitis; a much larger cohort
would, however, be necessary to investigate risk factors more con-
clusively. This is in contrast with the work on those treated for
mycobacterial infection with rifampicin, where alcohol excess, low
BMI, low serum albumin, age and gender have been suggested as
predisposing factors.10,11,23,24 Multi-centre studies will be needed to
further investigate potential risk factors for rifampicin-induced hep-
atitis in the context of liver disease.
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F IGURE 2 Course of serum alanine
aminotransferase activity measurements in
the five patients who developed
rifampicin-associated liver injury. Each dot
represents a test. Values are normalised to
the value recorded on the day of drug
initiation. Patient numbers correspond to
those presented in Table 2
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Our cohort included some 23 patients with a baseline serum
bilirubin of over 100 lmol/L ( ≥ 5.8 mg/dL). The UK package insert
of rifampicin states that its use is contra-indicated in jaundice,
although anecdotally many liver clinicians will consider using rifampi-
cin for the treatment of pruritus despite jaundice.25 We note, how-
ever, that it is our practice to co-prescribe oral vitamin K for icteric
patients receiving rifampicin to reduce the risk of coagulopathy.26
None of our markedly jaundiced patients developed hepatitis and we
note that a separately reported group of markedly jaundiced patients
with hepatocellular secretory failure predominantly attributed to bil-
iary transporters dysfunction are reported as having safely received
rifampicin for up to 10 weeks.27 Of our cohort, although one patient
required corticosteroids and admission to hospital, none of our 105
patients developed life-threatening complications from rifampicin
despite some having advanced liver disease at baseline. Given that
there was no established protocol for the monitoring of liver bio-
chemistry during the time period assessed, it is possible that some
further sub-clinical rifampicin-induced hepatitis may have escaped
diagnosis. Nevertheless, our results suggest that rifampicin therapy is
relatively safe in cholestatic jaundice.
Liver patients with cholestatic disorders may be prescribed multi-
ple therapeutic compounds and our cohort was taking a median of 5
nonrifampicin medications. Although this number did not vary
between groups that did and did not develop rifampicin-associated
hepatitis, we cannot exclude the potential for drug-drug interactions
promoting hepatitis, especially considering that over 20% of our
patients were taking long-term antibiotics, predominantly as prophy-
laxis against recurrent cholangitis. A further variable that cannot be
TABLE 2 Liver biochemistry at baseline and at diagnosis of rifampicin induced hepatitis
Patient 1 2 3b 4 5c
Major diagnosis PBC PSC PBC DILI PBC
Age (y) 55 28 37 26 43
Gender (M/F) M M F F F
Nonrifampicin prescriptions 6 3 6 3 4
RUCAM score 8 7 11 8 6
Variable Normal range Units Laboratory values at baseline
Bili <22 (lmol/L) 99 17 15 348 29
ALP 35-105 (F)/40-130 (M) (IU/L) 652 399 178 414 272
AST 5-43 (IU/L) 168 — 65 78 213
ALT 5-41 (IU/L) 85 95 41 86 221
Alb 34-51 (g/L) 37 41 44 41 45
Cr 50-111 (lmol/L) 71 71 63 61 59
eGFR — (mL/min) >90 >90 >90 >90 >90
INR 0.8-1.2 — 1.0 0.9 1.1 1.0 1.0
Eosinophils <0.4 9109/L 0.1 0.2 0.2 0.1 0.1
Time until diagnosisa — (d) 97 130 70 (14) 27 (20) 70
Variable Normal range Units Laboratory values at diagnosis
Bili <22 (lmol/L) 201 39 126 72 186
ALP 35-105 (F)/40-130 (M) (IU/L) 360 851 227 200 176
AST 5-43 (IU/L) 286 — 646 158 —
ALT 5-41 (IU/L) 186 557 492 310 1050
Alb 34-51 (g/L) 34 39 43 44 33
Cr 50-111 (lmol/L) 78 58 76 57 61
eGFR — (mL/min) 90 >90 74 >90 >90
INR 0.8-1.2 — 1.7 1.1 1.3 1.0 1.9
Eosinophils <0.4 9109/L 0.1 0.2 0.3 0.2 0.1
RUCAM, Roussel-Uclaf causality assessment method score where ≥ 6 represents probable drug (rifampicin)-induced hepatitis; PBC, primary biliary cholan-
gitis; PSC, primary sclerosing cholangitis; DILI, (cholestatic) drug-induced liver injury. Bili, serum bilirubin (lmol/L); ALP, alkaline phosphatase (IU/mL);
AST, aspartate aminotransferase (IU/mL); ALT, alanine aminotransferase (IU/mL); Alb, serum albumin (g/L); Cr, serum creatinine (lmol/L); INR, interna-
tional normalised ratio.
aDays from prescription to diagnosis, numbers in brackets indicate time from dose uptitration.
bPatient received a re-challenge with rifampicin after resolution of initial hepatitis which again provoked significant elevations in serum transaminase
activity.
cPatient admitted for treatment with corticosteroids.
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accounted for within the sample size of this mixed aetiology cohort
is interactions between rifampicin prescription and subtype of under-
lying cholestatic liver disease.
The median time to onset of hepatitis in our cohort was 70 days
from initiation of rifampicin therapy. Most of the patients were fol-
lowed up for longer than this period with the majority finding rifampi-
cin tolerable and effective. Notably our median time of 70 days until
onset of hepatitis is longer than the reported median interval to the
development of hepatitis in cohorts of tuberculosis patients of
approximately 15 to 30 days.24,28 Importantly, two of our patients
developed hepatitis after the end of the period of biochemical moni-
toring suggested by recent guidelines.8 We note that two of the
three cases of rifampicin-induced hepatitis reported by Prince et al
occurred at 11 and 14 months after drug initiation.15 Again, given
the absence of protocol liver biochemical monitoring and the retro-
spective nature of this study, it is possible that the number of cases
of rifampicin-induced hepatitis described here is an underestimate
with cases meeting our criteria potentially being missed.
Our study provides real-world experience of the use of rifampi-
cin in cholestatic pruritus. We demonstrate useful reference data for
clinicians who should counsel patients carefully: reassuringly 95% of
our patients did not develop any liver injury, and the 5% that did
develop hepatitis all recovered after drug cessation with only one
patient requiring further intervention. Many patients with marked
jaundice and advanced liver disease took rifampicin safely. In the
absence of alternative safe, licensed and equally effective agents,
clinicians may consider, the use of rifampicin in cholestatic pruritus.
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